10-Q: Talphera Secures $21M, Niyad Study Narrows Amid Going Concern Doubts

Talphera, Inc. reported a reduced net loss for the nine months ended September 30, 2025, bolstered by recent capital raises totaling $21.3 million, but continues to face substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the nine months ended September 30, 2025, was $10.5 million, an improvement from $11.1 million in the same period of 2024.
• Cash, cash equivalents, and short-term investments increased significantly to $21.3 million as of September 30, 2025, from $8.9 million at December 31, 2024.
• Operating costs and expenses decreased by $2.2 million for the nine months ended September 30, 2025, compared to the prior year, driven by reductions in R&D and SG&A.
• The company successfully raised approximately $17.0 million in gross proceeds from a September 2025 private placement and $4.9 million from the first closing of an April 2025 private placement.
• FDA agreed to reduce the Niyad NEPHRO CRRT study size from 166 to 70 patients and broadened inclusion criteria in March and January 2025, respectively.
• Substantial doubt exists regarding the company's ability to continue as a going concern, requiring additional capital within the next 12 months.
• All securities-related class action and shareholder derivative lawsuits against the company and its officers have been dismissed or terminated.

Sentiment

Score: 3

Explanation: While the company successfully raised capital and reduced its nine-month net loss, the explicit 'substantial doubt about going concern' and the continued need for significant future funding, coupled with the failure to meet a stock price condition for a prior capital raise, indicate a highly precarious financial position. The positive regulatory updates for Niyad are overshadowed by the severe liquidity concerns and the discontinuation of DSUVIA sales by Alora.

Positives

• Net loss for the nine months ended September 30, 2025, decreased to $10.5 million from $11.1 million in the prior year, indicating improved year-to-date financial performance.
• Total operating costs and expenses decreased by $2.2 million for the nine months ended September 30, 2025, compared to the prior year, reflecting cost reduction efforts.
• Cash, cash equivalents, and short-term investments significantly increased to $21.3 million as of September 30, 2025, from $8.9 million at December 31, 2024, due to recent financing activities.
• FDA agreed to reduce the Niyad NEPHRO CRRT study size from 166 to 70 patients, potentially accelerating development and reducing associated costs.
• FDA broadened Niyad NEPHRO CRRT study inclusion criteria, which may aid patient enrollment and study completion.
• Successfully regained compliance with Nasdaq's minimum bid price requirement on October 20, 2025.
• All previously disclosed securities-related class action and shareholder derivative lawsuits have been dismissed or terminated, removing significant legal overhangs.

Negatives

• Incurred a net loss of $4.4 million for the three months ended September 30, 2025, an increase from $3.4 million in the same period of 2024, indicating a worsening short-term financial performance.
• Accumulated deficit increased to $467.7 million as of September 30, 2025, reflecting continued unprofitability.
• Substantial doubt exists about the ability to continue as a going concern, requiring additional capital within the next 12 months.
• The second closing of the April 2025 Private Placement did not occur as the common stock's average volume weighted average price (VWAP) did not meet the $0.7325 per share condition.
• Alora Pharmaceuticals, LLC is discontinuing DSUVIA sales efforts to non-DoD customers, creating uncertainty for future DSUVIA-related payments.
• Interest income and other income, net, decreased by $343,000 for the nine months ended September 30, 2025, primarily due to lower average cash balances.
• Experienced a $793,000 loss on change in fair value of warrant liability for the nine months ended September 30, 2025, compared to a $306,000 gain in the prior year.

Risks

• Substantial doubt exists regarding the ability to continue as a going concern, requiring additional capital that may not be available on acceptable terms or at all.
• Failure to realize expected benefits from the acquisition of Lowell Therapeutics, Inc., which could adversely affect stock price.
• Delays in clinical trials are common and have many causes, and the Niyad clinical trial has experienced slower than expected site initiation and patient enrollment.
• Clinical trials of product candidates may fail to demonstrate safety and efficacy, leading to additional costs, delays, or inability to complete development.
• Difficulties in enrolling patients in clinical trials could delay or prevent necessary regulatory approvals.
• Identification of serious adverse effects or unexpected characteristics of product candidates during development may require abandonment or limitation of development.
• Limited resources may be expended on a particular product candidate or indication, failing to capitalize on more profitable opportunities.
• The process for obtaining Premarket Approval (PMA) or New Drug Application (NDA) is time-consuming, subject to unanticipated delays and costs, and requires substantial resources.
• Expectations for FDA approvability of product candidates may be inaccurate, potentially requiring additional manufacturing, nonclinical, or clinical development work.
• Inability to establish and maintain collaborative relationships, particularly for international sales, marketing, and distribution, could limit successful commercialization.
• Inability to retain existing employees and manage operations effectively, with potential disruptions from future workforce reductions.
• Inability to compete effectively in the U.S. biotechnology and pharmaceutical industries, which are characterized by intense competition and cost pressure.
• Coverage and adequate reimbursement may not be available for product candidates, if approved, making profitable sales difficult.
• Active enforcement by the FDA and other regulatory agencies against the promotion of off-label uses could lead to significant liability.
• Inability to establish and maintain relationships with group purchasing organizations (GPOs) could jeopardize future revenues.
• Existing and future legislation, such as the Affordable Care Act and Inflation Reduction Act, may increase the difficulty and cost of commercialization and affect prices.
• Reliance on third-party manufacturers and suppliers, including single sources for active pharmaceutical ingredients (API) and finished product for nafamostat-based candidates located outside the U.S. (e.g., China), poses risks of supply disruptions, quality issues, and trade restrictions.
• Manufacturing issues may arise that could delay or increase costs related to product development and regulatory approval.
• Reliance on third parties (CROs) to conduct, supervise, and monitor clinical trials, with limited influence over their performance.
• Relationships with healthcare professionals and partners are subject to anti-kickback, fraud, and abuse laws, potentially exposing the company to significant penalties.
• Significant disruptions of information technology systems or data security incidents could result in financial, legal, regulatory, business, and reputational harm.
• Business interruptions, such as natural disasters (e.g., earthquakes in the San Francisco Bay Area), could delay operations and sales efforts.
• Future success depends on the ability to retain key executives and attract, retain, and motivate qualified personnel.
• Potential product liability claims, which, if successful, could result in substantial liability not fully covered by insurance.
• Litigation involving patents, patent applications, and other proprietary rights is expensive and time-consuming and could cause delays.
• Inability to enforce intellectual property rights throughout the world, especially in countries with less robust legal systems.
• The market price of common stock has historically been and may continue to be highly volatile.
• Sales of a substantial number of shares of common stock in the public market could cause the stock price to fall.
• Provisions in the amended and restated certificate of incorporation and bylaws, as well as Delaware law, could make it more difficult for a third party to acquire the company.
• Macroeconomic uncertainties, including tariffs, inflationary pressures, supply chain disruptions, labor shortages, significant volatility in global markets, and recession risks, may adversely affect the business.
• Limitations on the ability to use net operating loss carryforwards and certain other tax attributes due to ownership changes or expiration.
• Fluctuations in the effective tax rate and adverse effects from changes in tax laws and regulations.

Future Outlook

The company expects to continue incurring significant losses and negative cash flows from operations in the future as it funds research and development activities for its product candidates. Additional capital will be needed to fund planned operations prior to November 12, 2026, and the company plans to seek this through various financing methods, including equity offerings, debt, asset monetization, or licensing agreements. The ability to generate significant near-term revenues from product candidates, if approved, is not anticipated. The company is working to facilitate a longer-term supply arrangement for DSUVIA following Alora's decision to discontinue non-DoD sales, but success is not assured.

Management Comments

• "We expect to continue to incur substantial expenses as we support research and development activities for our product candidates."
• "If our product candidates are not successfully developed or commercialized in the U.S., or if revenues are insufficient following marketing approval, we will not achieve profitability and our business may fail."
• "While we believe our plans to raise additional funds will alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, these plans are not entirely within our control and cannot be assessed as being probable of occurring."
• "If adequate funds are not available, we may be required to further reduce our workforce, delay, reduce the scope of, or cease, the development of our product candidates in advance of the date on which our cash resources are exhausted to ensure that we have sufficient capital to meet our obligations and continue on a path designed to preserve stockholder value."
• "We are working to attempt to facilitate a longer-term supply arrangement for DSUVIA, but there are no assurances we will be successful."

Industry Context

The company operates in the highly competitive and cost-pressured U.S. biotechnology and pharmaceutical industries, focusing on specialty pharmaceuticals for medically supervised settings. Its lead candidate, Niyad, targets regional anticoagulation for dialysis, an area with existing treatments like heparin and citrate. The broader industry faces increasing regulatory scrutiny, cost containment pressures from government and private payers, and evolving trade policies, including tariffs, which could impact supply chains and development costs. The company's strategy to expand its portfolio with acute care therapies aligns with a trend towards specialized solutions in hospital settings.

Comparison to Industry Standards

• The company's recurring operating losses and negative cash flows are common for early-stage biopharmaceutical companies focused on R&D, but the explicit "substantial doubt about going concern" indicates a more critical financial position compared to well-capitalized industry peers.
• The reduction in clinical trial size for Niyad (NEPHRO CRRT study from 166 to 70 patients) and broadened inclusion criteria, agreed upon with the FDA, could be seen as a positive regulatory development, potentially accelerating time to market compared to typical lengthy clinical trial timelines.
• The reliance on single-source suppliers for active pharmaceutical ingredients (API) and finished products, particularly from China, is a common industry risk but is heightened by current geopolitical trade tensions and supply chain disruptions, potentially placing the company at a disadvantage compared to companies with diversified supply chains.
• The successful dismissal of securities class action and shareholder derivative lawsuits is a favorable outcome, contrasting with the ongoing legal challenges faced by some larger pharmaceutical companies, particularly those involved with opioid products.
• The capital raises, while significant for the company, come with substantial dilution to existing shareholders, a common trade-off for small-cap biotech firms needing to fund extensive R&D.

Management Changes

Corporate Governance

Legal Proceedings

• Securities class action complaint (filed June 8, 2021, amended March 7, 2022) alleging violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 regarding DSUVIA marketing and disclosure controls, and Section 20A for alleged insider trading. The District Court dismissed the complaint with prejudice on May 7, 2024, and the Ninth Circuit affirmed this dismissal on August 20, 2025.
• Four purported shareholder derivative complaints (filed July 6, 2021, September 30, 2021, October 26, 2021, and November 17, 2021) asserting state and federal claims based on the same alleged misstatements as the securities class action. These were consolidated and stayed, then terminated on September 30, 2025, following the Ninth Circuit's order in the securities class action.
• Another purported shareholder derivative complaint (filed February 16, 2024, in Delaware) asserting similar claims. This case was stayed and subsequently dismissed by the plaintiff on October 8, 2025, in light of the Ninth Circuit's order.

Related Party Transactions

• A member of management participated in the April 2025 Private Placement.

Stakeholder Impact

• Shareholders: Significant dilution from recent and potential future equity offerings; stock price volatility risk remains high; potential for a future acquisition by CorMedix or another party; continued risk of value erosion due to going concern doubts.
• Employees: Risk of further workforce reductions if additional capital is not secured; challenges in retaining and attracting qualified personnel due to financial uncertainty.
• Customers: Potential delays in product development and commercialization (e.g., Niyad, LTX-608) could impact future product availability; uncertainty regarding DSUVIA supply.
• Suppliers: Supply chain disruptions, particularly for single-source components from outside the U.S., could affect product development and manufacturing.
• Creditors: Increased risk due to the "going concern" doubt and reliance on future capital raises to meet obligations.

Next Steps

• Raise additional capital through public or private equity offerings, debt securities, a new debt facility, asset monetization, or product development/license agreements.
• Continue the Niyad NEPHRO CRRT clinical study, now with a reduced patient size of 70 and broadened inclusion criteria.
• Advance the development of LTX-608 for indications such as ARDS, DIC, acute pancreatitis, or as an anti-viral treatment.
• File registration statements for the resale of shares and underlying warrants from the September 2025 and April 2025 Private Placements.
• Potentially complete the second closing of the September 2025 Private Placement (additional $12.0 million) upon Niyad NEPHRO CRRT study primary endpoint achievement and VWAP condition, or waiver.
• Potentially complete remaining tranches of the April 2025 Private Placement (up to $8.2 million) if purchasers waive conditions or milestones are met.
• Work to facilitate a longer-term supply arrangement for DSUVIA following Alora's discontinuation of non-DoD sales.
• CorMedix may designate a board member if its ownership threshold is met.
• Engage in exclusive negotiations with CorMedix for a potential acquisition of 100% of the company's capital stock following the public announcement of Niyad NEPHRO CRRT study primary endpoint and topline data.

Key Dates

Recommendation

Despite recent capital raises and some positive regulatory developments for Niyad, the explicit "substantial doubt about our ability to continue as a going concern" is a severe red flag for investors. The company continues to incur significant losses and requires substantial additional capital within the next 12 months, with no guarantee of securing it on favorable terms. The failure of a contingent capital raise tranche due to unmet stock price conditions, coupled with the discontinuation of DSUVIA sales by Alora, further highlights the precarious financial and operational outlook. While legal proceedings have been resolved favorably, the fundamental financial instability and high execution risk for its product pipeline, combined with potential significant future dilution, make the stock a high-risk investment with a strong likelihood of further downside.

Keywords

Talphera, TLPH, SEC Filing, 10-Q, Quarterly Report, Biopharmaceutical, Specialty Pharmaceutical, Niyad, Nafamostat, LTX-608, NEPHRO CRRT, Clinical Trials, FDA Approval, Going Concern, Capital Raise, Private Placement, CorMedix, Warrants, Stock Dilution, Drug Development, Acute Kidney Injury, Dialysis, Anticoagulant, ARDS, DIC, Acute Pancreatitis, Nasdaq Compliance, Financial Results, Operating Loss, Cash Flow, Risk Factors, Intellectual Property, Corporate Governance